Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2014 | Research

Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies

Authors: Jie Yang, Jia-yi Zhang, Jing Chen, Chen Chen, Xiao-meng Song, Yang Xu, Jie Li

Published in: World Journal of Surgical Oncology | Issue 1/2014

Abstract

Background

Recent studies show that microRNA-145 (miR-145) might be an attractive tumor biomarker of considerable prognostic value. To clarify the preliminary predictive value of miR-145 for prognosis in various malignant neoplasms, we conducted a meta-analysis of 18 relevant studies.

Methods

Eligible studies were identified by searching the online databases PubMed, EMBASE, and Web of Science up to March 2014. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease progress were calculated to investigate the association with miR-145 expression.

Results

In total, 18 eligible studies were included in this meta-analysis. Our results showed that upregulated miR-145 significantly predicted a favorable overall survival (OS) (HR = 0.47, 95% CI 0.31 to 0.72), but failed to show a significant relation with disease prognosis. In stratified analyses, high miR-145 expression predicted favorable OS in both Whites and Asians but the intensity of the association in Whites (HR = 0.67, 95% CI 0.47 to 0.95) was not as strong as in Asians (HR = 0.35, 95% CI 0.19 to 0.64). High miR-145 expression also predicted better progression-free survival (PFS) in Asians (HR = 0.43, 95% CI 0.21 to 0.89), but not in Whites. In addition, a significantly favorable OS associated with upregulated miR-145 expression was observed in both squamous cell (SCC) (HR = 0.34, 95% CI 0.13 to 0.93) and glioblastoma (HR = 0.72, 95% CI 0.52 to 0.99).

Conclusions

Our findings indicate that high miR-145 expression is better at predicting patient survival rather than disease progression for malignant tumors, especially for SCC and glioblastoma in Asians. Considering the insufficient evidence, further investigations and more studies are needed.

Available only for authorised users

Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013, 52 (4): 297-303.CrossRefPubMed

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: microRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838.CrossRefPubMed

Wang QZ, Xu W, Habib N, Xu R: Potential uses of microRNA in lung cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets. 2009, 9 (4): 572-594.CrossRefPubMed

Rong M, Chen G, Dang Y: Increased MiR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer. 2013, 13: 21-PubMedCentralCrossRefPubMed

Lee HK, Bier A, Cazacu S, Finniss S, Xiang C, Twito H, Poisson LM, Mikkelsen T, Slavin S, Jacoby E, Yalon M, Toren A, Rempel SA, Brodie C: microRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One. 2013, 8 (2): e54652-PubMedCentralCrossRefPubMed

Haapa-Paananen S, Chen P, Hellström K, Kohonen P, Hautaniemi S, Kallioniemi O, Perälä M: Functional profiling of precursor MicroRNAs identifies MicroRNAs essential for glioma proliferation. PLoS One. 2013, 8 (4): e60930-PubMedCentralCrossRefPubMed

Campayo M, Navarro A, Viñolas N, Diaz T, Tejero R, Gimferrer JM, Molins L, Cabanas ML, Ramirez J, Monzo M, Marrades R: Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer. Eur Respir J. 2013, 41 (5): 1172-1178.CrossRefPubMed

Shi B, Sepp-Lorenzino M, Prisco M, Linsley P, de Angelis T, Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem. 2007, 282: 32582-32590.CrossRefPubMed

Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, Wong N: miR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis. 2012, 33 (6): 1134-1141.CrossRefPubMed

10.

Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009, 106 (9): 3207-3212.PubMedCentralCrossRefPubMed

11.

Yu CC, Tsai LL, Wang ML, Yu CH, Lo WL, Chang YC, Chiou GY, Chou MY, Chiou SH: miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res. 2013, 73 (11): 3425-3440.CrossRefPubMed

12.

Ko MA, Zehong G, Virtanen C, Guindi M, Waddell TK, Keshavjee S, Darling GE: microRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy. Ann Thorac Surg. 2012, 94 (4): 1094-1102. discussion 1102–3CrossRefPubMed

13.

Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Dall'Oglio MF, Camara-Lopes LH, Srougi M: microRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol. 2011, 185 (3): 1118-1122.CrossRefPubMed

14.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283: 2008-2012.CrossRefPubMed

15.

Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998, 17 (24): 2815-2834.CrossRefPubMed

16.

Williamson PR, Smith CT, Hutton JL, Marson AG: Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002, 21 (22): 3337-3351.CrossRefPubMed

17.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into metaanalysis. Trials. 2007, 8: 16-PubMedCentralCrossRefPubMed

18.

DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188.CrossRefPubMed

19.

Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315 (7109): 629-634.PubMedCentralCrossRefPubMed

20.

Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A: The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer. 2013, 108 (12): 2573-2581.PubMedCentralCrossRefPubMed

21.

Tang M, Lin L, Cai H, Tang J, Zhou Z: MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patientssuffering osteosarcoma. Onco Targets Ther. 2013, 6: 833-838.PubMedCentralPubMed

22.

Tanaka K, Miyata H, Yamasaki M, Sugimura K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y: Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer. Ann Surg Oncol. 2013, 20 (Suppl 3): S607-S615.CrossRefPubMed

23.

Speranza MC, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M, Pellegatta S, Finocchiaro G: NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012, 3 (7): 723-734.PubMedCentralCrossRefPubMed

24.

Kang SG, Ha YR, Kim SJ, Kang SH, Park HS, Lee JG, Cheon J, Kim CH: Do microRNA 96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma?. Asian J Androl. 2012, 14 (5): 752-757.PubMedCentralCrossRefPubMed

25.

Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K: Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012, 12: 505-PubMedCentralCrossRefPubMed

26.

Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M: Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012, 7 (3): e33762-PubMedCentralCrossRefPubMed

27.

Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M: Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 2011, 12 (3): 273-285.CrossRefPubMed

28.

Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011, 10 (3): 507-517.CrossRefPubMed

29.

Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH, Nakajima K, Takiguchi S, Fujiwara Y, Mori M, Doki Y: Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011, 17 (9): 3029-3038.CrossRefPubMed

30.

Drebber U, Lay M, Wedemeyer I, Vallböhmer D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP, Odenthal M: Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol. 2011, 39 (2): 409-415.PubMed

31.

Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, Guo H, Guo L: MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). Eur J Cancer. 2013, 49 (3): 710-724.CrossRefPubMed

32.

Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P: MicroRNA-155 is required for effector CD8 (+) T cell responses to virus infection and cancer. Immunity. 2013, 38 (4): 742-753.PubMedCentralCrossRefPubMed

33.

Manavalan TT, Teng Y, Litchfield LM, Muluhngwi P, Al-Rayyan N, Klinge CM: Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One. 2013, 8 (4): e62334-PubMedCentralCrossRefPubMed

34.

Fu G, Brkić J, Hayder H, Peng C: MicroRNAs in human placental development and pregnancy complications. Int J Mol Sci. 2013, 14 (3): 5519-5544.PubMedCentralCrossRefPubMed

35.

DeCastro AJ, Dunphy KA, Hutchinson J, Balboni AL, Cherukuri P, Jerry DJ, DiRenzo J: miR203 mediates subversion of stem cell properties during mammary epithelial differentiation via repression of ΔNP63α and promotes mesenchymal-to-epithelial transition. Cell Death Dis. 2013, 4: e514-PubMedCentralCrossRefPubMed

36.

Ferracin M, Veronese A, Negrini M: Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn. 2010, 10: 297-308.CrossRefPubMed

37.

Kim DJ, Linnstaedt S, Palma J, Park JC, Ntrivalas E, Kwak-Kim JY, Gilman-Sachs A, Beaman K, Hastings ML, Martin JN, Duelli DM: Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn. 2012, 14 (1): 71-80.PubMedCentralCrossRefPubMed

38.

Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola FM, Tucker MA, Bertazzi PA, Pesatori AC, Caporaso NE, McShane LM, Wang E: MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010, 16: 430-441.PubMedCentralCrossRefPubMed

39.

Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, Su TJ, Chiang CC, Li HN, Hong QS, Su HY, Chen CC, Chen WJ, Liu CC, Chan WK, Chen WJ, Li KC, Chen JJ, Yang PC: MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008, 13: 48-57.CrossRefPubMed

40.

Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, Liu J, Tabatabai ZL, Kakar S, Deng G, Tanaka Y, Dahiya R: MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011, 32: 772-778.PubMedCentralCrossRefPubMed

41.

Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K: Modulation of microRNA processing by p53. Nature. 2009, 460: 529-533.CrossRefPubMed

42.

Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT: Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010, 24 (24): 2754-2759.PubMedCentralCrossRefPubMed

43.

Sachdeva M, Liu Q, Cao J, Lu Z, Mo YY: Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res. 2012, 40 (14): 6683-6692.PubMedCentralCrossRefPubMed

44.

Yazici H, Zipprich J, Peng T, Akisik EZ, Tigli H, Isin M, Akisik EE, Terry MB, Senie RT, Li L, Peng M, Liu Z, Dalay N, Santella RM: Investigation of the miR16-1 (C > T) + 7 substitution in seven different types of cancer from three ethnic groups. J Oncol. 2009, 2009: 827532-PubMedCentralCrossRefPubMed

45.

Bovell LC, Shanmugam C, Putcha BD, Katkoori VR, Zhang B, Bae S, Singh KP, Grizzle WE, Manne U: The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res. 2013, 19 (14): 3955-3965.PubMedCentralCrossRefPubMed

46.

Huang RS, Gamazon ER, Ziliak D, Wen Y, Im HK, Zhang W, Wing C, Duan S, Bleibel WK, Cox NJ, Dolan ME: Population differences in microRNA expression and biological implications. RNA Biol. 2011, 8 (4): 692-701.PubMedCentralCrossRefPubMed

47.

Liu R, Liao J, Yang M, Sheng J, Yang H, Wang Y, Pan E, Guo W, Pu Y, Kim SJ, Yin L: The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One. 2012, 7 (3): e33987-PubMedCentralCrossRefPubMed

Title: Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies
Authors: Jie Yang
Jia-yi Zhang
Jing Chen
Chen Chen
Xiao-meng Song
Yang Xu
Jie Li
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-12-254

At a glance: The STEP trials

Springer Medicine

Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Application of intraoperative frozen section examination in the management of female breast cancer in China: a nationwide, multicenter 10-year epidemiological study

Inflammatory pseudotumor of the liver diagnosed as metastatic liver tumor in a patient with a gastrointestinal stromal tumor of the rectum: report of a case

MicroRNA expression profiling and Notch1 and Notch2 expression in minimal deviation adenocarcinoma of uterine cervix

Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma

Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer

Does young age influence the prognosis of colorectal cancer: a population-based analysis